Literature DB >> 30160829

Novel phenotype of achondroplasia due to biallelic FGFR3 pathogenic variants.

Irene J Chang1, Angela Sun2, Maryse L Bouchard3, Shawn E Kamps4,5, Susan Hale2,3, Stephen Done4, Michael J Goldberg3, Ian A Glass1,2.   

Abstract

Pathogenic variants in the fibroblast growth factor receptor 3 (FGFR3) gene are responsible for a broad spectrum of skeletal dysplasias, including achondroplasia (ACH). The classic phenotype of ACH is caused by two highly prevalent mutations, c.1138G > A and c.1138G > C (p.Gly380Arg). In the homozygous state, these variant results in a severe skeletal dysplasia, neurologic deficits, and early demise from respiratory insufficiency. Although homozygous biallelic mutations have been reported in patients with ACH in combination with hypochondroplasia or other dominant skeletal dysplasias, thus far, no cases of heterozygous biallelic pathogenic ACH-related variants in FGFR3 have been reported. We describe a novel phenotype of an infant with two ACH-related mutations in FGFR3, p.Gly380Arg and p.Ser344Cys. Discordant features from classic ACH include atypical radiographic findings, severe obstructive sleep apnea, and focal, migrating seizures. We also report the long-term clinical course of her father, who harbors the p.Ser344Cys mutation that has only been reported once previously in a Japanese patient. The phenotype of heterozygous biallelic mutations in FGFR3 associated with ACH is variable, underscoring the importance of recognition and accurate diagnosis to ensure appropriate management.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  ACH; FGFR3; SADDAN; achondroplasia; hypochondroplasia; platyspondyly; seizures; skeletal dysplasia

Mesh:

Substances:

Year:  2018        PMID: 30160829      PMCID: PMC6121735          DOI: 10.1002/ajmg.a.38839

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  28 in total

1.  Homozygous achondroplasia: morphologic and biochemical study of cartilage.

Authors:  R Stanescu; V Stanescu; P Maroteaux
Journal:  Am J Med Genet       Date:  1990-11

2.  Lethal skeletal dysplasia owing to double heterozygosity for achondroplasia and spondyloepiphyseal dysplasia congenita.

Authors:  I D Young; N R Ruggins; J M Somers; J M Zuccollo; N Rutter
Journal:  J Med Genet       Date:  1992-11       Impact factor: 6.318

3.  A novel mutation Ser344Cys in FGFR3 causes achondroplasia with severe platyspondyly.

Authors:  Masaki Takagi; Masanori Kouwaki; Koya Kawase; Hiroyuki Shinohara; Yukihiro Hasegawa; Takahiro Yamada; Ikuma Fujiwara; Hideaki Sawai; Gen Nishimura; Tomonobu Hasegawa
Journal:  Am J Med Genet A       Date:  2015-06-30       Impact factor: 2.802

4.  Common mutations in the fibroblast growth factor receptor 3 (FGFR 3) gene account for achondroplasia, hypochondroplasia, and thanatophoric dwarfism.

Authors:  J Bonaventure; F Rousseau; L Legeai-Mallet; M Le Merrer; A Munnich; P Maroteaux
Journal:  Am J Med Genet       Date:  1996-05-03

5.  Mild achondroplasia/hypochondroplasia with acanthosis nigricans, normal development, and a p.Ser348Cys FGFR3 mutation.

Authors:  Natario L Couser; Chetna K Pande; Christie M Turcott; Elaine B Spector; Arthur S Aylsworth; Cynthia M Powell
Journal:  Am J Med Genet A       Date:  2017-02-09       Impact factor: 2.802

6.  Double heterozygosity for pseudoachondroplasia and spondyloepiphyseal dysplasia congenita.

Authors:  S Unger; J Korkko; D Krakow; R S Lachman; D L Rimoin; D H Cohn
Journal:  Am J Med Genet       Date:  2001-11-22

7.  FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway.

Authors:  M Sahni; D C Ambrosetti; A Mansukhani; R Gertner; D Levy; C Basilico
Journal:  Genes Dev       Date:  1999-06-01       Impact factor: 11.361

8.  Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism.

Authors:  W C Su; M Kitagawa; N Xue; B Xie; S Garofalo; J Cho; C Deng; W A Horton; X Y Fu
Journal:  Nature       Date:  1997-03-20       Impact factor: 49.962

9.  Achondroplasia-hypochondroplasia complex.

Authors:  A Sommer; T Young-Wee; T Frye
Journal:  Am J Med Genet       Date:  1987-04

10.  Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Authors:  Keith Nykamp; Michael Anderson; Martin Powers; John Garcia; Blanca Herrera; Yuan-Yuan Ho; Yuya Kobayashi; Nila Patil; Janita Thusberg; Marjorie Westbrook; Scott Topper
Journal:  Genet Med       Date:  2017-05-11       Impact factor: 8.822

View more
  2 in total

Review 1.  FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer.

Authors:  Alec Kacew; Randy F Sweis
Journal:  Front Immunol       Date:  2020-11-05       Impact factor: 7.561

2.  Bilious Vomiting in the Newborn: A Three-Year Experience in a Tertiary Medical and Surgical Centre.

Authors:  Rebecca A Lee; Theodore Dassios; Ravindra Bhat; Anne Greenough
Journal:  Case Rep Pediatr       Date:  2020-10-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.